AUROPHARMA.NSE · Aurobindo Pharma Limited

-

Please sign in to comment on AUROPHARMA.NSE

1 Comment

Admin

5 years, 4 months ago

Aurobindo Pharma Limited is currently in a long term uptrend where the price is trading 6.4% above its 200 day moving average.

From a valuation standpoint, the stock is 56.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.

Aurobindo Pharma Limited's total revenue rose by 7.8% to $64B since the same quarter in the previous year.

Its net income has increased by 317.7% to $29B since the same quarter in the previous year.

Finally, its free cash flow fell by 5.6% to $21B since the same quarter in the previous year.

Based on the above factors, Aurobindo Pharma Limited gets an overall score of 4/5.

ABOUT

Aurobindo Pharma Limited

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

AUROPHARMA.NSE · Aurobindo Pharma Limited

-

Aurobindo Pharma Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Aurobindo Pharma Limited using a moving average strategy